Novo unveils new research grant to mark World Haemophilia Day
Novo Nordisk has marked World Haemophilia Day 2016 with the announcement of a new research grant aimed at supporting and encouraging research projects focused on the psychological issues faced by people living with the condition.
The HERO (haemophilia experiences, results, opportunities) research grant is worth up to €75,000 and, as part of the global campaign, Novo is calling on people to take part in spreading the message by using the hashtags #MeetTheHERO and #WHD2016.
Globally, it is estimated that 440,000 people have haemophilia. It is a blood clotting disorder that is characterised by internal bleeding into the joints, muscles, and other tissues can cause severe pain, joint damage, and disability. The HERO study encompasses the psychosocial experiences of people with haemophilia, their families and their health care providers and covers a range of themes.
Paul Huggins, corporate VP at Novo Nordisk, says: “The HERO research grant is part of our commitment to helping people with haemophilia live a life with fewer limitations and support the heroes who care for them.”
Novo’s campaign supports the World Federation of Haemophilia campaign ‘Treatment for all, the vision of all’. The research grant is available to healthcare professionals providing care for people with haemophilia, and social workers or equivalent who provide or have expertise in psychosocial support for people with haemophilia.
Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing …
Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent …